Josh Kushner's Thrive Capital and Alphabet (NASDAQ:GOOG) are leading new financing for Isomorphic Labs, an AI-powered drug discovery company.



The London-based company, spun out of Google DeepMind, plans to raise $2 billion to expand its business globally, Bloomberg reported.



Isomorphic, founded in 2021 by DeepMind co-founder Demis Hassabis, functions as a &#34;digital biology&#34; lab aimed at revolutionizing the pharmaceutical industry by designing novel medicines using machine learning.



<div>




Read Also:

Brookfield Asset Management CEO Says AI Is A 'Significant Tailwind' Amid Strong Q1 Growth




</div>


Earlier this year, the company announced that it had entered into an agreement to expand its research collaboration with Novartis, adding up to three additional research programs. Isomorphic has also entered into major strategic partnerships with Eli Lilly and Johnson and Johnson.



In March 2025, Isomorphic announced it had raised $600 million in its first-ever external funding round, led by Thrive Capital. Other investors included Google Ventures and Alphabet, the New York Times had reported at the time.



Last month, former Disney CEO Bob Iger rejoined Thrive as an advisor, working with the company's investment staff and portfolio founders.



New York City-based Thrive Capital was founded in 2009 and focuses on software investments. The firm manages more than $50 billion in assets, according to Pitchbook and TechCrunch.



Thrive has also backed several well-known companies, including SpaceX, Stripe, and OpenAI.



<div>




Read Also:

Apollo Explores $3 Billion Sale Of Private Credit Fund MFIC




</div>


Photo: Shutterstock

GOOG

GOOGL

ELIL

LLYZ

GGLL

Thrive Capital and Alphabet are leading a $2 billion fundraising effort for Isomorphic Labs, an AI-driven drug discovery company spun out of Google DeepMind. Founded in 2021 by Demis Hassabis, Isomorphic aims to revolutionize pharmaceuticals through machine learning. The company has secured strategic partnerships with Novartis, Eli Lilly, and Johnson & Johnson. Thrive Capital, managing over $50 billion in assets, has previously invested in notable firms like SpaceX and OpenAI.

- Thrive Capital and Alphabet are leading a new financing effort for Isomorphic Labs, which specializes in AI-driven drug discovery.  
- The London-based company aims to raise $2 billion for global expansion and has formed significant partnerships with Novartis, Eli Lilly, and Johnson & Johnson.  
- Isomorphic, founded by DeepMind co-founder Demis Hassabis in 2021, previously raised $600 million in a funding round led by Thrive Capital.

benzinga_article

Johnson & Johnson

Eli Lilly

Alphabet - C

Novartis AG

Alphabet

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Short LLY ETF

Direxion Daily GOOGL Bull 2X Shares

NOVARTIS AG

New York Times

Disney

Stripe

OpenAI

Brookfield Asset

Apollo Global

APOLLO GLOBAL MANAGEMENT INC 6.75% CONV PFD STK SER A

Apollo Global Management Pref Share APO 7.625 09/15/53

Thrive Capital, Alphabet To Lead Isomorphic Labs $2 Billion Fundraising Goal